A recent Tax Appeal Commission case gives an insight into the flow of monies surrounding the supply of a particular drug, and the Vat treatment of the supply of drugs in general. The Appellant in the tax case is a drug company. While the drug is not named, it is described as an innovative treatment requiring ongoing use i.e. not a one-off cure. The first link in the financial chain is the sale of the drug, by the drug company, to an authorised wholesaler at a defined “ex-factory price”, calculated as the maximum of an average sales price in a…
Cancel at any time. Are you already a member? Log in here.
Want to read the full story?
Unlock this article – and everything else on The Currency – with an annual membership and receive a free Samsonite Upscape suitcase, retailing at €235, delivered to your door.